Idorsia Pharmaceuticals Gmbh

**Idorsia Announces FDA Approval for New Treatment** **Radnor, PA, USA - [Date]** - Idorsia Pharmaceuticals US today announced the approval of a new treatment by the US Food and Drug Administration (FDA). This approval marks a significant milestone for Idorsia, a leading Swiss biopharmaceutical company dedicated to developing novel therapies for patients with unmet medical needs. Idorsia US was established to ensure that patients in the United States can benefit from the company's innovative products. The company has its headquarters at One Radnor Corporate Center in Radnor, Pennsylvania. Idorsia Pharmaceuticals Germany GmbH is a German subsidiary of Idorsia Ltd. and is dedicated to providing patients in Germany with access to the company's therapies. For more information about Idorsia and its commitment to improving patient outcomes, please visit the company's websites listed below: * Idorsia Pharmaceuticals Ltd: https://www.idorsia.com/ * Idorsia Pharmaceuticals Germany GmbH: https://www.idorsia.de/ * Idorsia US: https://www.idorsia.us/